Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ

Nature Medicine

Volumn 4, Issue 4, 1998, Pages 408-414

  Rüegg, Curzio ^a   Yilmaz, Aysim ^a   Bieler, Grégory ^a   Bamat, Jeannine ^b   Chaubert, Pascal ^c   Lejeune, Ferdy J ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c University of Lausanne Medical Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN; FIBRINOGEN; FIBRONECTIN; GAMMA INTERFERON; INTEGRIN; LYSOPHOSPHATIDIC ACID; MANGANESE CHLORIDE; MELPHALAN; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR; VITRONECTIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL ADHESION; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VASCULARIZATION;

APOPTOSIS; BIOPSY; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INTERFERON TYPE II; MELANOMA; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 0040887215     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0498-408     Document Type: Article

References (50)

1. Carswell, E.A. et al. An endotoxin-induced serum factor that causes necrosis of tumors Proc. Natl. Acad. Sci. USA 72, 3666-3670 (1975).
2. Liénard, D., Ewalenko, P., Delmotte, J.J., Renard, N. & Lejeune, F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52-60(1992).
3. Lejeune, F.J. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer, fur. J. Cancer 6, 1009-1016 (1995).
4. Liénard, D. et al. Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha (TNF-alpha), interferon gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 4, Suppl. 1, 21-26 (1994).
5. Renard, N. et al. von Willenbrand Factor release and platelet aggregation in human melanoma after perfusion with TNFα. J. Pathol. 176, 279-287 (1995).
6. Renard, N. et al. Early endothelium activation and polymorphonuclear cell invasion preceed specific necrosis of human melanoma and sarcoma treated by intravascular high dose of Tumor Necrosis Factor alpha. Int. J. Cancer 57, 656-663 (1994).
7. Enenstein, J. & Kramer, R.H. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J. Invest. Dermatol. 103, 381-386 (1994).
8. Brooks, P.C., Clark, R.A. & Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571 (1994).
9. Max, R. et al. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int. J. Cancer 71, 320-324 (1997).
10. Brooks, P.C. et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
11. Brooks, P.C. et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 (1995).
12. Stromblad, S., Becker, J.C., Yebra, M., Brooks, P.C. & Cheresh, D.A. Suppression of p53 activity and p21 WAF1/CIP1 expression by vascular cell integrin alpha v beta 3 during angiogenesis. J. Clin. Invest. 98, 426-433 (1996).
13. Defilippi, P. et al. Tumor necrosis factor alpha and interferon gamma modulate the expression of the vitronectin receptor (integrin beta 3) in human endothehal cells. J. Biol. Chem. 266, 7638-7645 (1991).
14. Schwartz, M.A., Schaller, M.D. & Ginsberg, M.H. Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Dev. Biol. 11, 549-599 (1995).
15. Clark, E.A. & Brugge, J.S. Integrins and signal transduction pathways: the road taken. Science 268, 233-239 (1995).
16. Nobes, C.D. & Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of multi-molecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62 (1995).
17. Smith, J.W., Piotrowicz, R.S. & Mathis, D. A mechanism for divalent cation regulation of beta 3-integrins. J. Biol. Chem. 269, 960-967 (1994).
18. Honda, S. et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J. Biol. Chem. 270, 11947-11954 (1995).
19. Pelletier, A.J., Kunicki, T. & quaranta, V. Activation of the integrin alpha V beta 3 involves a discrete cation-binding site that regulates conformation. J. Biol. Chem. 271, 1364-1370 (1996).
20. Meredith, J., Jr., Fazeli, B. & Schwartz, M.A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4, 953-961 (1993).
21. Re, F. et al. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J. Cell Biol. 127, 537-546 (1994).
22. Frisch, S.M. & Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619-626 (1994).
23. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-30 (1995).
24. Lejeune, F. et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J. Cell. Biochem. 56, 52-61 (1994).
25. Brooks P.C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85, 683-693 (1996).
26. Stromblad, S. & Cheresh, D.A. Cell adhesion and angiogenesis. Trends Cell Biol. 6, 462-468 (1996).
27. Campbell, J.J., Qin, S., Bacon, K.B., Mackay, C.R. & Butcher, E.C. Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J. Cell Biol. 134, 255-266 (1996).
28. Vassboth, F.S., Havnen, O.K., Heldin, C.H. & Holmsen, H. Negative feedback regulation of human platelets via autocrine activation of the platelet derived growth factor alpha receptor. J. Biol. Chem. 269, 13874-13879 (1994).
29. Dahl, S.C. & Grabel, L.B. Integrin phosphorylation is modulated during the differentiation of F-9 teratocarcinoma stem cells. J. Cell Biol. 108, 183-190 (1989).
30. Adams, J.C. & Watt, F.M. Changes in keratinocyte adhesion during terminal differentiation: reduction in fibronectin binding precedes alpha 5 beta 1 integrin loss from the cell surface. Cell 63, 425-435 (1990).
31. Neugebauer, K.M. & Reichardt, L.F. Cell-surface regulation of beta 1-integrin activity on developing retinal neurons. Nature 350, 68-71 (1991).
32. Boettiger, D. et al. Regulation of integrin alpha 5 beta 1 affinity during myogenic differentiation. Dev. Biol. 169, 261-272 (1995).
33. Hughes, P.E. et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88, 521-530 (1997).
34. Tominaga, T. et al. Inhibition of PMA-induced, LFA-1-dependent lymphocyte aggregation by ADP ribosylation of the small molecular weight GTP binding protein, rho. J. Cell Biol. 120, 1529-1537 (1993).
35. Saklatvala, J., Rawlinson, L.M., Marshall, C.J. & Kracht, M. Interleukin 1 and tumour necrosis factor activate the mitogen-activated protein (MAP) kinase kinase in cultured cells. Febs Letters 334, 189-192 (1993).
36. Belka, C. et al. Tumor necrosis factor (TNF)-alpha activates c-raf-1 kinase via the p55 TNF receptor engaging neutral sphingomyelinase. Embo J. 14, 1156-1165 (1995).
37. Xia, K. et al. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21 ras-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 93, 11681-11686 (1996).
38. Doukas, J. & Pober, J.S. IFN-γ enhances endothelial activation induced by tumor necrosis factor but not IL-1. J. Immunol. 145, 1727-1733 (1990).
39. Marfaing-Koka, A. et al. Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-γ plus TNF-α and inhibition by IL-4 and IL-13. J. Immunol. 154, 1870-1878 (1995).
40. Pandita, R., Pocsik, E. & Aggarwal, B.B. Interferon-gamma induces cell surface expression for both types of tumor necrosis factor receptors. Febs Letters 312, 87-90 (1992).
41. Ohmori, Y. & Hamilton, T.A. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-γ and TNF-alpha. J. Immunol. 154, 5235-5244 (1995).
42. Johnson, D.R. & Pober, J.S. HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Molec. Cel. Biol. 14, 1322-1332 (1994).
43. Lejeune, F.J., Lienard, D., Schraffordt Koops, H., Kroon, B. & Eggermont, A.M.M. Treatment of in-transit melanoma metastases with Tumor Necrosis Factor (TNF) and chemotherapy administered in isolated limb perfusion (ILP). Melanoma Res. 7, S48 (1997).
44. Digne, A.S., Richards, E., Old, L.J. & Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1, 447-456 (1994).
45. Sato, T.N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995).
46. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 (1996).
47. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
48. Spertini, O. et al. Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J. Immunol. 147, 2565-2573 (1991).
49. Gérain, J., Lienard, D., Ewalenko, P. & Lejeune, F.J. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. Cytokine 4, 585-591 (1992).
50. Lahm, H. et al. Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int. J. Cancer 59, 440-447 (1994).